GLIADEL WAFER carmustine 7.7mg/implant implant sachet Австралія - англійська - Department of Health (Therapeutic Goods Administration)

gliadel wafer carmustine 7.7mg/implant implant sachet

eisai australia pty ltd - carmustine, quantity: 7.7 mg - implant - excipient ingredients: polifeprosan - gliadel is indicated in newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. gliadel is also indicated for use as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme (gbm) for whom surgical resection is indicated.

TAKHZYRO lanadelumab 300 mg/2 mL solution for injection pre-filled syringe Австралія - англійська - Department of Health (Therapeutic Goods Administration)

takhzyro lanadelumab 300 mg/2 ml solution for injection pre-filled syringe

takeda pharmaceuticals australia pty ltd - lanadelumab, quantity: 300 mg - injection, solution - excipient ingredients: citric acid monohydrate; water for injections; dibasic sodium phosphate dihydrate; polysorbate 80; histidine; sodium chloride - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years and older.

Serenade Optimum Нова Зеландія - англійська - Ministry for Primary Industries

serenade optimum

bayer new zealand limited - bacillus subtilis qst 713 - wettable powder - bacillus subtilis qst 713 1.46 b cfu/g - fungicide - fungicide

ADENOSCAN adenosine 30mg/10mL injection vial Австралія - англійська - Department of Health (Therapeutic Goods Administration)

adenoscan adenosine 30mg/10ml injection vial

sanofi-aventis australia pty ltd - adenosine, quantity: 30 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - intravenous adenoscan is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.

ADENOCOR Adenosine 6mg/2mL injection Австралія - англійська - Department of Health (Therapeutic Goods Administration)

adenocor adenosine 6mg/2ml injection

sanofi-aventis australia pty ltd - adenosine, quantity: 3 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - therapeutic indications: rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (wolff-parkinson-white syndrome). diagnostic indications: aid to diagnosis of broad or narrow complex supraventricular tachycardias. although adenocor is not effective in converting atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of av conduction helps diagnosis of atrial activity. in this respect adenosine should be used as an adjunct to, but not a replacement for, clinical and ecg observations. it should be only used when, despite all diagnostic attempts, doubt still persists. improved diagnostic sensitivity of intracavity electrophysiological investigations

Crusader GoDRI Herbicide Австралія - англійська - APVMA (Australian Pesticides and Veterinary Medicines Authority)

crusader godri herbicide

corteva agriscience australia pty ltd - cloquintocet acid; pyroxsulam - water dispersible granule - cloquintocet acid acid active 451.5 g/kg; pyroxsulam sulfonamide active 215.0 g/kg - herbicide

DEMADEX- torsemide tablet США - англійська - NLM (National Library of Medicine)

demadex- torsemide tablet

meda pharmaceuticals - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - demadex is indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. demadex is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with demadex. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure educ

demadex- torsemide tablet
demadex- torsemide injection, solution США - англійська - NLM (National Library of Medicine)

demadex- torsemide tablet demadex- torsemide injection, solution

roche pharmaceuticals - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - tablet - 5 mg - demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. demadex intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. demadex is contraindicated in patients with known hypersensitivity to demadex or to sulfonylureas. demadex is contraindicated in patients who are anuric.

DEMADEX- torsemide tablet США - англійська - NLM (National Library of Medicine)

demadex- torsemide tablet

physicians total care, inc. - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 20 mg - demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. demadex is contraindicated in patients with known hypersensitivity to demadex or to sulfonylureas. demadex is contraindicated in patients who are anuric.